GBM heterogeneity explains therapy failure. Xie et al. characterize the essential role of quiescent cancer stem cells in therapy resistance and tumor recurrence. This study highlights the importance of integrating quiescent cancer stem cells in the design and evaluation of therapeutics for GBM patients.